Takeda Pharmaceutical Company Limited (TYO:4502)
Japan
· Delayed Price · Currency is JPY 4,366.00
+9.00 (0.21%)
Aug 14, 2025, 3:30 PM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.11T JPY in the quarter ending June 30, 2025, a decrease of -8.39%. This brings the company's revenue in the last twelve months to 4.48T, up 1.52% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4,480.25B
Revenue Growth
+1.52%
P/S Ratio
1.52
Revenue / Employee
94.41M
Employees
47,455
Market Cap
6,819.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.22B |
| HOYA Corporation | 876.09B |
| Daiichi Sankyo Company | 1,924.68B |
| Otsuka Holdings | 2,401.70B |
| Terumo | 1,037.94B |
| Astellas Pharma | 1,944.99B |
| Shionogi & | 440.50B |
| Olympus | 969.02B |
Takeda Pharmaceutical Company News
- 6 days ago - Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis - Newsfile Corp
- 14 days ago - Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales - Benzinga
- 14 days ago - Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales - Benzinga
- 14 days ago - Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Takeda Pharmaceutical Non-GAAP EPS of ¥151.00, revenue of ¥1106.7B; reaffirms FY outlook - Seeking Alpha
- 15 days ago - Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression - Business Wire
- 15 days ago - Insights Ahead: Takeda Pharmaceutical's Quarterly Earnings - Benzinga
- 24 days ago - Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration - Business Wire